<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277897</url>
  </required_header>
  <id_info>
    <org_study_id>XAXT-2019-001</org_study_id>
    <nct_id>NCT04277897</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses of Hepenofovir Fumarate Tablets in Healthy Volunteers.</brief_title>
  <official_title>A Phase Ia Single-center,Randomized,Double-blind,Placebo-controled Study to Investigate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses of Hepenofovir Fumarate Tablets in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xi'an Xintong Pharmaceutical Research Co.,Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xi'an Xintong Pharmaceutical Research Co.,Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Investigate the Safety, Tolerability, Pharmacokinetics of Single and Multiple
      Doses of Hepenofovir Fumarate Tablets in Healthy Volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It's a single-center,randomized, double-blind, placebo-controlled study. It will assess the
      safety, tolerability, and pharmacokinetics of single and multiple orally administered doses
      of Hepenofovir Fumarate Tablets in healthy adult subjects.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 6 Days in SAD Cohorts</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 12 Days in MAD Group</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 13 Days in Food-influence Group</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>Drug SAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepenofovir Fumarate Tablets Dose 1, Dose 2, Dose 3, Dose 4 and Dose 5 orally, once daily in one single administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SAD Cohorts</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, orally, once daily in one single administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug MAD Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepenofovir Fumarate Tablets Dose 3 orally, once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MAD Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, orally, once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Food-influnced Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepenofovir Fumarate Tablets Dose 4 orally, once daily in one single administration in fast condition,cross-over 7 days later in fed condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hepenofovir Fumarate Tablets Single Dose</intervention_name>
    <description>Oral Tablet; Subjects will receive either a single dose of Hepenofovir Fumarate Tablets on Day 1 only (SAD), once daily dosing of HTS starting on Day 1 through Day 7 (MAD).</description>
    <arm_group_label>Drug MAD Group</arm_group_label>
    <arm_group_label>Drug SAD Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match Hepenofovir Fumarate Tablets</description>
    <arm_group_label>Placebo MAD Group</arm_group_label>
    <arm_group_label>Placebo SAD Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hepenofovir Fumarate Tablets Dose4</intervention_name>
    <description>Oral Tabet; Subjects will receive Hepenofovir Fumarate Tablets Dose4 on Day 1 in fast condition, then receive Hepenofovir Fumarate Tablets Dose4 on Day 8 in fed condition.</description>
    <arm_group_label>Food-influnced Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to understand the nature of the study, comply with the protocol, and provide
             informed consent.

          -  Subjects willing to adhere to protocol requirements and to finish the study.

          -  Subjects were willing to use methods of contraception from the time of screen to 6
             months post the last dose administration.

          -  Subjects aged between 18 and 55 years (both inclusive).

          -  Subject's weight within normal range according to normal values for Body Mass Index
             (19.00 to 26.00 kg/m2 (both inclusive)) ,with minimum of 50 kg weight for male, 45 kg
             weight for famale.

          -  Subjects with normal health as determined by personal medical history, clinical
             examination and laboratory examinations within clinically acceptable normal range.

        Exclusion Criteria:

          -  History or presence of significant smoking (more than 5 cigarettes/day prior to 3
             months the first dose of the study drug).

          -  Hypersensitivity to different kinds of drugs and food.

          -  Presence of significant alcoholism or drug abuse.

          -  Volunteer who have donated blood or lose blood(&gt;450mL)within past 90 days prior to the
             first dose of the study drug.

          -  Any treatment which could bring about induction or inhibition of hepatic microsomal
             enzyme system within 28 days prior to dosing of the study.

          -  Use of any prescribed medication or OTC medicinal products during the last 14 days
             prior to dosing of the study.

          -  Consumption of spcial food(including gragon fruit, mango, grapefruits) or strenuous
             excercise,or other factors which may effect the
             absorption,distribution,metabolism,excretion of drugs for within 2 weeks prior to
             dosing of the study.

          -  Any treatment which could bring about induction or inhibition of CYP3A4.

          -  Volunteer who have participation in a drug research study within past 90 days prior to
             the first dose of the study drug.

          -  Difficulty in swallowing or other gastrointestinal disease or disorder.

          -  Presence of an abnormal electrocardiogram (ECG), which was clinically significant.

          -  Female subjects who were breast-feeding or had a positive pregnancy test at screening
             or at any time during the study.

          -  Subjects with abnormal health as determined by personal medical history, clinical
             examination and laboratory examinations,which was clinically significant.

          -  Subjects who, in the opinion of the Investigator, should not participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

